An anti-VEGFR-2 effect of vandetanib at 100 mg and 300 mg is also supported by an exploratory pharmacodynamic study in patients with breast cancer, which showed inhibition of VEGFR-2 phosphorylation in skin biopsy tissue after 28 days of vandetanib treatment [29]. This evidence concerns the gene KDR and breast cancer.